Breast Cancer

Latest News

Patient satisfaction was higher amongst women who underwent chest wall perforator flap technique when compared with other techniques.| Image Credit: AdobeStock_ H_Ko.jpeg
Patient Satisfaction Higher With Certain Breast Reconstruction Techniques

August 12th 2025

Patient satisfaction was higher amongst patients who underwent a chest wall perforator flap reconstruction surgery as part of their breast cancer treatment when compared with other surgical techniques.

Supplemental breast cancer screenings criteria leaves Black women ineligible despite high percentage of false-negative mammograms. | Image Credit: breastcancerscreening-H_Ko.jpeg
Supplemental Breast Cancer Screening Law Renders Many High-Risk Black Women Ineligible

August 5th 2025

Black women are at a higher risk for breast cancer mortality due to social determinants of health and lack of inclusivity in breast cancer genome research. | Image credit: Stafeeva - stock.adobe.com.jpeg
Social Disparities Increase Breast Cancer Mortality for Black Women

July 27th 2025

Early-onset breast cancer found to be associated with certain hormone therapy usage in younger women. | Image Credit: Chinnapong - stock.adobe.com
Hormone Therapy Use May Impact Early-Onset Breast Cancer Risk

July 26th 2025

Menopausal hormone therapy is associated with a higher risk of developing certain breast cancer subtypes. | Image Credit: vectorfusionart - stock.adobe.com
Hormone Therapy Use Differentially Associated With Breast Cancer Subtypes

July 16th 2025

Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

Experts discuss the impact of CDK4/G inhibitor use, including medication cost, total care costs, toxicity profiles, and strategies to manage and optimize patient outcomes in high-risk early breast cancer.

Watch the latest AJMC Peer Exchange on Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

More News

Evidence-Based Oncology
December 23rd 2020

Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Brenna L. Brady, PhD Matthew Lucci, MPH Kathleen Wilson, MPH Kathleen M. Fox, PhD Jeffrey Wojtynek, PharmD Chelsea Cooper, PharmD Helen Varker, BS Christina Larson Chebili, MA Igoni Dokubo, MD
This article describes treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.
Evidence-Based Oncology
December 23rd 2020

Supplemental Material: Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Brenna L. Brady, PhD Matthew Lucci, MPH Kathleen Wilson, MPH Kathleen M. Fox, PhD Jeffrey Wojtynek, PharmD Chelsea Cooper, PharmD Helen Varker, BS Christina Larson Chebili, MA Igoni Dokubo, MD
Supplemental materials for the article describing treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.
FDA
December 23rd 2020

MacroGenics’ Margenza Approved for Metastatic Breast Cancer

Maggie L. Shaw
The FDA has approved Margenza (margetuximab-cmkb) plus chemotherapy as a treatment option for adults with HER2-postive advanced breast cancer.
Top 5 breast cancer articles
December 21st 2020

Top 5 Most-Read Breast Cancer Articles of 2020

Maggie L. Shaw
These top 5 posts from our breast cancer compendium in 2020 show that while much is known about breast cancer, much remains that can help to broaden the knowledge armamentarium.
Alexey Aleshin, MD, Natera
December 18th 2020

Dr Alexey Aleshin: I-SPY 2 Findings Show How We Can Dynamically Monitor ctDNA

Patient plasma samples from this study show residual circulating tumor DNA (ctDNA) correlates with a poor prognosis in women with early-stage breast cancer, explained Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera.
Pink breast cancer ribbon with figures
December 14th 2020

Uptick in Early-Stage Breast Cancer Diagnoses Seen Among Minority Women Following ACA Implementation

Maggie L. Shaw
Compared with before the Affordable Care Act (ACA), study results show there was an increase in diagnoses of early-stage breast cancer among younger vs older minority women after the act.
Alexey Aleshin, MD, Natera
December 12th 2020

Dr Alexey Aleshin Highlights the Diagnostic Benefits of ctDNA in Early-Stage Breast Cancer

Circulating tumor DNA (ctDNA) has a host of benefits in treating and managing patients with early-stage disease, noted Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera.
Obesity May Fuel 40% Gap in Black, White Breast Cancer Mortality
December 7th 2020

Obesity May Fuel 40% Gap in Black, White Breast Cancer Mortality

Maggie L. Shaw
Overall survival from early breast cancer has steadily been increasing; however, simultaneous increases in obesity and obesity-related comorbidities may have contributed to the survival disparity seen between these patient groups.
Doctor evaluating mammography.
December 5th 2020

Social Determinants of Health May Influence Undiagnosed Breast Cancer Risk

Maggie L. Shaw
Research presented at this year’s annual meeting of the Radiological Society of North America shows the possible impact of food or housing insecurity on follow-up appointments for breast cancer.
Silhouette of pregnant woman
December 1st 2020

Fertility Preservation Linked to Uptick in Live Births Following Breast Cancer

Maggie L. Shaw
Survival after breast cancer is on the rise, thereby emphasizing the importance of discussions that focus on fertility and reproduction among younger survivors.
Puzzle-piece graphic for breast cancer gene
November 27th 2020

10-Year BRCA Testing Decreases, Study Shows

Maggie L. Shaw
Among older women with and without breast and ovarian cancers, testing for the BRCA gene dropped precipitously between 2008 and 2018.
Aditya Bardia, MBBS, MPH, Massachusetts General Hospital
November 25th 2020

Dr Aditya Bardia Highlights Immuno-Oncology Developments for Patients With TNBC

Tecentriq (atezolizumab) was approved in 2019 for PD-L1–positive triple-negative breast cancer (TNBC), said Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.
Group of women
November 19th 2020

Younger, Minority Women With Metastatic Breast Cancer Using More EOL Care

Maggie L. Shaw
Patients younger than 65 years represent close to 40% of deaths from metastatic breast cancer, yet their use of end-of-life (EOL) care has not been thoroughly investigated until now.
Mammography image
November 17th 2020

Women With Dense Breast Tissue May Benefit From Abbreviated Breast MRI

Maggie L. Shaw
Supplemental screening for breast cancer, beyond the standard-of-care mammography, may benefit some women who have dense breast tissue.
HRT Associated With Higher Breast Cancer Risk
November 13th 2020

HRT Associated With Higher Breast Cancer Risk, Study Finds

Rose McNulty
A recent study published in The BMJ suggests that the increased breast cancer risk varies by hormone replacement therapy (HRT) type, but that combined treatments and longer duration might lead to the highest risk.
Bilateral Mastectomy Possibly Linked to Poor Self-Image Among Young Breast Cancer Survivors
November 10th 2020

Bilateral Mastectomy Possibly Linked to Poor Self-Image Among Young Breast Cancer Survivors

Maggie L. Shaw
A recent study of female breast cancer survivors shows that feelings toward body image were consistently worse among those who had a bilateral mastectomy vs breast-conserving surgery.
Elderly woman alone
November 7th 2020

Study Results Point to Possible Survival Link Between Elderly Age, Chemotherapy

Maggie L. Shaw
Having node-positive, estrogen receptor–positive breast cancer indicated a greater likelihood of overall survival following chemotherapy, despite having several comorbidities, after adjustment for confounders.
Breast Cancer Survivor
November 2nd 2020

Black Patients With Breast Cancer May Face Longer Waits, Treatment Duration

Rose McNulty
A recent analysis identified disparities in the start of breast cancer treatment and the duration of treatment in Black women compared with White women.
Aditya Bardia, MBBS, MPH, Massachusetts General Hospital
November 1st 2020

Dr Aditya Bardia: Further Research Is Needed to Understand Resistance to Sacituzumab Govitecan

Despite FDA accelerated approval in April, we still need to learn more about resistance to this antibody drug conjugate, said Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.
Axillary Surgery Approach Impacts BCRL Risk in Breast Cancer Patients
October 28th 2020

Axillary Surgery Approach Impacts BCRL Risk in Breast Cancer Patients

Rose McNulty
A study published in the Journal of Clinical Oncology determined that the main risk factor for breast cancer-related lymphedema in patients with positive axillary lymph nodes is the type of axillary surgery used.
Aditya Bardia, MBBS, MPH, Massachusetts General Hospital
October 25th 2020

Dr Aditya Bardia Forecasts What’s to Come for the ASCENT Trial in Triple-Negative Breast Cancer

Initial preliminary efficacy and safety data are expected sometime next year, stated Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.
This Week in Managed Care for the week of October 19
October 23rd 2020

This Week in Managed Care: October 23, 2020

This week, the top managed care news included COVID-19 delays in breast cancer surgery; targeted therapies associated with decreased mortality risk for non–small cell lung cancer; an inside look at a patient’s perspective of early-onset Parkinson disease.
Breast Cancer Survivor
October 20th 2020

COVID-19 Delays in Breast Cancer Surgery Could Mean More Deaths Over Next Decade

Rose McNulty
A new analysis predicts close to 3000 additional deaths over a 10-year period in patients who faced delays in breast cancer treatment during the pandemic.
Timothy Yap, MBBS, MD Anderson
October 19th 2020

Dr Timothy Yap Reiterates the Unmet Medical Need for Molecularly Targeted Agents in Solid Tumors

Early results on rucaparib/sacituzumab govitecan are promising, but further exploration is needed, stated Timothy A. Yap, MBBS, PhD, FRCP, medical director of the Institute for Applied Cancer Science, MD Anderson Cancer Center.
breast cancer
October 12th 2020

Ductal Carcinoma in Situ Associated With Higher Breast Cancer Death Risk

Rose McNulty
Findings suggest that current standard treatment does not eliminate the risk of breast cancer-specific death in the 20 years after DCIS diagnosis.
Aditya Bardia, MBBS, MPH, Harvard Medical School
October 12th 2020

Dr Aditya Bardia on How Combining Sacituzumab Govitecan, Talazoparib Amplifies Treatment Response

There is a synthetic lethality between sacituzumab govitecan and a PARP inhibitor, noted Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.
Dr Timothy Yap: PARP/TOP1 Inhibitor Toxicities Can Be Managed Through Targeted Delivery
October 5th 2020

Dr Timothy Yap: PARP/TOP1 Inhibitor Toxicities Can Be Managed Through Targeted Delivery

Targeted tumor delivery of irinotecan through sacituzumab govitecan can help to reduce treatment-related toxicities, noted Timothy A. Yap, MBBS, PhD, FRCP, medical director of the Institute for Applied Cancer Science, MD Anderson Cancer Center.
Mortality Higher Among Women With Interval vs Screening-Detected Breast Cancers
October 1st 2020

Mortality Higher Among Women With Interval vs Screening-Detected Breast Cancers

Maggie L. Shaw
Results from a study on Canadian women who did and did not participate in a population-based breast cancer screening program show that interval breast cancers are more aggressive and deadlier than screening-detected cancers.
Dr Aditya Bardia Discusses the Advantages of Sacituzumab Govitecan for Triple-Negative Breast Cancer
September 28th 2020

Dr Aditya Bardia Discusses the Advantages of Sacituzumab Govitecan for Triple-Negative Breast Cancer

There is a clear need for better therapies to treat triple-negative breast cancer, especially when progression-free survival is around 2%, says Aditya Bardia, MBBS, MPH, breast medical oncologist at Massachusetts General Hospital, Harvard Medical School.
Timothy Yap, MBBS, MD Anderson
September 25th 2020

Dr Timothy Yap: Rucaparib/Sacituzumab Govitecan Combo Effective Against Triple-Negative Disease

A novel combination shows promise against advanced solid tumors, including triple-negative breast cancer, noted Timothy A. Yap, MBBS, PhD, FRCP, medical director of the Institute for Applied Cancer Science at MD Anderson Cancer Center.
<1
...
45678910111213>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo